DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo


company name or ticker

Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syn

Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research

Don't Write Off Arena As Yet

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog

Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog

Jefferies: 10 Buyout Targets To Own During The M&A Boom

Vivus Sales Remain Flat - Stock Trend Not Good

Arena's 15,000 Scripts Set Pace Vs. Competitors

The Best Stock to Invest in Obesity Drugs

Making money helping people shed the pounds.

Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More

Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider

See More Articles...